Odronextamab + REGN5837
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Non-Hodgkins Lymphoma (B-NHL)
Conditions
B-cell Non-Hodgkins Lymphoma (B-NHL)
Trial Timeline
Apr 12, 2023 → May 16, 2029
NCT ID
NCT05685173About Odronextamab + REGN5837
Odronextamab + REGN5837 is a phase 1 stage product being developed by Regeneron Pharmaceuticals for B-cell Non-Hodgkins Lymphoma (B-NHL). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05685173. Target conditions include B-cell Non-Hodgkins Lymphoma (B-NHL).
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05685173 | Phase 1 | Recruiting |
Competing Products
20 competing products in B-cell Non-Hodgkins Lymphoma (B-NHL)